Market capitalization | $114.62m |
Enterprise Value | $138.85m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.02 |
P/S ratio (TTM) P/S ratio | 1.67 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 29.34% |
Revenue (TTM) Revenue | $68.65m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a TELA Bio Inc forecast:
5 Analysts have issued a TELA Bio Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 69 69 |
29%
29%
|
|
Gross Profit | 47 47 |
28%
28%
|
|
EBITDA | -45 -45 |
11%
11%
|
EBIT (Operating Income) EBIT | -46 -46 |
11%
11%
|
Net Profit | -42 -42 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
Head office | United States |
CEO | Antony Koblish |
Employees | 227 |
Founded | 2012 |
Website | www.telabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.